Merck & Co., Inc. (MRK) Competitors & Peers
The 5 companies closest to Merck & Co., Inc. on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Competitor | $1,231.94 | P/E 39.8RSI 61Cap 1.10 T |
| JNJ | Peer | $261.15 | P/E 30.3RSI 57Cap 629.3 B |
| ABBV | Competitor | $248.80 | P/E 69.7RSI 51Cap 439.7 B |
| AZN | Peer | $161.91 | P/E 24.2RSI 40Cap 251.1 B |
| NVS | Peer | $156.79 | P/E 23.6RSI 55Cap 298.0 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- BMYCompetitor
Bristol-Myers Squibb (Opdivo) and Merck (Keytruda) are the two dominant competitors in PD-1/PD-L1 checkpoint inhibitor oncology.
Confirmed — SEC filing / public disclosuresec.gov ↗ - RIGLSupplier
Own 10-K customer-concentration disclosure: MerckSeronoSA = 89% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKSupplier
McKesson is one of Merck's primary wholesale distributors for pharmaceutical products in the US.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- MRNAPartner
Merck-Moderna individualized neoantigen therapy (mRNA-4157/V940) + Keytruda combo in Phase III melanoma.
Model-inferred, unverified — treat as a lead, not evidence - DSNKYPartner
Merck-Daiichi Sankyo $22B ADC pipeline collaboration (3 candidates).
Model-inferred, unverified — treat as a lead, not evidence - BMYCompetitor
Keytruda vs Opdivo immuno-oncology.
Model-inferred, unverified — treat as a lead, not evidence - OGNSupplier
Merck provides transitional supply and manufacturing services for Organon's established brand products.
Model-inferred, unverified — treat as a lead, not evidence - PFECompetitor
Top pharma majors.
Model-inferred, unverified — treat as a lead, not evidence - LLYCompetitor
Lilly Keytruda equivalent competition.
Model-inferred, unverified — treat as a lead, not evidence - LLYCompetitor
Merck and Eli Lilly compete in oncology and diabetes — Merck's Januvia vs Lilly's Jardiance in type-2 diabetes.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson is Merck distributor.
Model-inferred, unverified — treat as a lead, not evidence - CAHSupplier
Cardinal distributes Merck.
Model-inferred, unverified — treat as a lead, not evidence - CORSupplier
Cencora distributes Merck.
Model-inferred, unverified — treat as a lead, not evidence - SMMTCompetitor
Summit's ivonescimab competes directly with Merck's blockbuster immunotherapy Keytruda.
Model-inferred, unverified — treat as a lead, not evidence - CORSupplier
Cencora is one of Merck's three primary wholesale distributors in the US market.
Model-inferred, unverified — treat as a lead, not evidence - TGTXCompetitor
Competes in multiple sclerosis therapeutic spaces.
Model-inferred, unverified — treat as a lead, not evidence - IBRXCompetitor
Competes in bladder cancer therapeutics, where ImmunityBio's Anktiva is used in combination with or competes with Merck's BCG therapy.
Model-inferred, unverified — treat as a lead, not evidence - VEEVSupplier
Merck uses Veeva Vault Clinical and Regulatory across its global pipeline.
Model-inferred, unverified — treat as a lead, not evidence - ABBVCompetitor
Merck competes with AbbVie in immunology (Keytruda checkpoint inhibitor vs AbbVie's Rinvoq/Skyrizi in overlapping indications like urothelial cancer/IBD).
Model-inferred, unverified — treat as a lead, not evidence - VEEVSupplier
Merck uses Veeva Vault across global pipeline.
Model-inferred, unverified — treat as a lead, not evidence - PFEPartner
Pfizer and Merck co-promote Eliquis (apixaban) globally — Pfizer developed it, Bristol-Myers Squibb and Pfizer co-own it, and Merck co-promotes in certain markets.
Model-inferred, unverified — treat as a lead, not evidence